AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29472262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation and moderation analysis of family harmony, parenting style, and neighbourhood conditions
Number of subjects: 254
Study 29472310 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) plus Bevacizumab (Bev)
Number of subjects: 66
Study 29472357 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 0
Study 29472362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa 80 mg
Number of subjects: 23
Study 29472362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa 160 mg
Number of subjects: 23
Study 29472362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa (both doses)
Number of subjects: 23
Study 29473059 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid expansion (intervention group)
Number of subjects: 990
Study 29473059 — intervention group
Group type: COMPARATOR
Intervention: No Medicaid expansion (control group)
Number of subjects: 990
Study 29473191 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity, blood pressure, cardiorespiratory fitness (CRF), muscle strength, body composition, and bone mineral density measurements
Number of subjects: 156
Study 29473191 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with BN
Number of subjects: 156
Study 29473191 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with BED
Number of subjects: 156
Study 29473191 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with a history of anorexia nervosa (AN)
Number of subjects: 156
Study 29473191 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall physical fitness in participants with BN or BED
Number of subjects: 156
Study 29474102 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care visits addressing coping
Number of subjects: 171
Study 29474102 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care visits addressing treatment decisions
Number of subjects: 171
Study 29474102 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care visits addressing advance care planning
Number of subjects: 171
Study 29474286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules (implemented in April to September 2016)
Number of subjects: 167
Study 29474286 — intervention group
Group type: COMPARATOR
Intervention: No cranberry capsules (April to September 2015)
Number of subjects: 167
Study 29474293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal reconstructive surgery
Number of subjects: 364
Study 29474293 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients younger than 60 years
Number of subjects: 364
Study 29474293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 364
Study 29474293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication use prior to surgery
Number of subjects: 364
Study 29474293 — intervention group
Group type: EXPERIMENTAL
Intervention: No concomitant midurethral sling
Number of subjects: 364
Study 29474293 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating times greater than 210 minutes
Number of subjects: 364
Study 29474293 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting history of depression
Number of subjects: 364
Study 29474336 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocan concentrations in critically ill hematology patients
Number of subjects: 744
Study 29474336 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocan levels in patients with acute respiratory failure
Number of subjects: 744
Study 29474336 — intervention group
Group type: EXPERIMENTAL
Intervention: Total endocan levels higher than 4.46 ng/mL
Number of subjects: 744
Study 29474336 — intervention group
Group type: EXPERIMENTAL
Intervention: Total endocan levels at admission
Number of subjects: 744
Study 29474336 — intervention group
Group type: COMPARATOR
Intervention: Endocan levels in critically ill hematology patients compared to healthy subjects
Number of subjects: 744
Study 29474345 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine titrated in the postanaesthesia care unit (PACU) and patient-controlled intravenous analgesia for 24 hours.
Number of subjects: 404
Study 29474345 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-related adverse events observed in patients.
Number of subjects: 404
Study 29474345 — intervention group
Group type: EXPERIMENTAL
Intervention: P-glycoprotein polymorphisms (ex-21; ex-26) analysis.
Number of subjects: 404
Study 29474345 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms (OPRM1, ABCB1, COMT) analysis.
Number of subjects: 404
Study 29474450 — intervention group
Group type: EXPERIMENTAL
Intervention: Native heterodimeric IL-15 (hetIL-15) treatment
Number of subjects: 2
Study 29474565 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham Risk Score (FRS)
Number of subjects: 3015
Study 29474565 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy recommendation
Number of subjects: 3015
Study 29474588 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (p-PCI)
Number of subjects: 7982
Study 29474588 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 7982
Study 29474588 — intervention group
Group type: COMPARATOR
Intervention: No reperfusion therapy (Control)
Number of subjects: 7982
Study 29474621 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold
Number of subjects: 0
Study 29474621 — intervention group
Group type: COMPARATOR
Intervention: XIENCE everolimus-eluting metallic stent
Number of subjects: 0
Study 29474723 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare costs after myocardial infarction (MI)
Number of subjects: 97252
Study 29474723 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resource use patterns
Number of subjects: 97252
Study 29474723 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term healthcare consumption
Number of subjects: 97252
Study 29475630 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insufficiency
Number of subjects: 0
Study 29475723 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbralisib (TGR-1202) administered orally once per day in 28-day cycles, starting dose of 50 mg, escalating to 1200 mg, with 800 mg of micronised formulation selected as the recommended phase 2 dose.
Number of subjects: 90
Study 29475723 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbralisib (TGR-1202)
Number of subjects: 90
Study 29475762 — intervention group
Group type: EXPERIMENTAL
Intervention: rBV A/B vaccine (0.5 mL, 40-microgram intramuscular injection)
Number of subjects: 45
Study 29476021 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab Pre- and Post-BEAM
Number of subjects: 0
Study 29476021 — intervention group
Group type: COMPARATOR
Intervention: Control group (without Rituximab)
Number of subjects: 0
Study 29476383 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib 150 mg orally twice daily on a 28-day cycle
Number of subjects: 17
Study 29476383 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib
Number of subjects: 17
Study 29476443 — intervention group
Group type: EXPERIMENTAL
Intervention: Two trabecular micro-bypass stents
Number of subjects: 80
Study 29476499 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix
Number of subjects: 1624
Study 29476612 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal fragment of pre-pro-vasopressin (copeptin) measured at admission and re-measured at 72 hours
Number of subjects: 164
Study 29476612 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 164
Study 29476612 — intervention group
Group type: EXPERIMENTAL
Intervention: mid-regional pro-atrial natriuretic peptide (MR-proANP)
Number of subjects: 164
Study 29476612 — intervention group
Group type: EXPERIMENTAL
Intervention: mid-regional pro-adrenomedullin (MR-proADM)
Number of subjects: 164
Study 29476612 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal pro-endothelin-1 (CT-proET1)
Number of subjects: 164
Study 29476660 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra leadless pacemaker implantation and concurrent AVJ ablation
Number of subjects: 21
Study 29476840 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 57
Study 29476840 — intervention group
Group type: COMPARATOR
Intervention: Control (off MPH)
Number of subjects: 57
Study 29476876 — intervention group
Group type: COMPARATOR
Intervention: No specific smoking cessation intervention
Number of subjects: 1081
Study 29477307 — intervention group
Group type: EXPERIMENTAL
Intervention: trivalent oral poliovirus vaccine (tOPV)
Number of subjects: 265
Study 29477307 — intervention group
Group type: EXPERIMENTAL
Intervention: monovalent OPV 2 (mOPV2)
Number of subjects: 265
Study 29477307 — intervention group
Group type: EXPERIMENTAL
Intervention: tOPV together with a dose of inactivated poliovirus vaccine (IPV)
Number of subjects: 265
Study 29477307 — intervention group
Group type: EXPERIMENTAL
Intervention: monovalent high-potency IPV type 2 with mOPV2
Number of subjects: 265
Study 29477307 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 265
Study 29477379 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of activated and expanded Natural Killer cells (NKAE) from haploidentical donors
Number of subjects: 18
Study 29477379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of IL-2
Number of subjects: 18
Study 29477412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 20 mg / Quinidine 10 mg (DM/Q) twice daily for 90 days
Number of subjects: 120
Study 29477578 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity (DPA) and energy expenditure (EE) assessed over 48 hours using a wearable armband system
Number of subjects: 41
Study 29477578 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity (IS) measured by euglycaemic insulin clamp
Number of subjects: 41
Study 29477578 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-cell function (BF) estimated by prolonged-OGTT minimal modeling
Number of subjects: 41
Study 29477778 — intervention group
Group type: EXPERIMENTAL
Intervention: Carlecortemcel-L (expanded cord blood units with cytokines and tetraethylenepentamine)
Number of subjects: 101
Study 29477778 — intervention group
Group type: COMPARATOR
Intervention: Double-unit cord blood transplantation (DUCBT)
Number of subjects: 101
Study 29477796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive programme of radiological investigations (maximal approach)
Number of subjects: 0
Study 29477796 — intervention group
Group type: COMPARATOR
Intervention: Symptom-driven surveillance (minimal approach)
Number of subjects: 0
Study 29478020 — intervention group
Group type: EXPERIMENTAL
Intervention: Predialysis CKD patients
Number of subjects: 3000
Study 29478027 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-specific AF6 questionnaire
Number of subjects: 54
Study 29478027 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic 36-Item Short-Form Health Survey
Number of subjects: 54
Study 29478027 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AF burden
Number of subjects: 54
Study 29478027 — intervention group
Group type: COMPARATOR
Intervention: Comparison with Swedish age- and sex-matched population
Number of subjects: 54
Study 29478026 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (β1-adrenergic receptor blocker) - monotherapy
Number of subjects: 699
Study 29478026 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (β1-adrenergic receptor blocker) - add-on therapy
Number of subjects: 699
Study 29478148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal antetheca submucosal-retropubic space mesh repair surgery
Number of subjects: 316
Study 29478343 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (human IgG1 monoclonal antibody against PD-L1)
Number of subjects: 0
Study 29478343 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 29478347 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose MMR
Number of subjects: 7436
Study 29478790 — intervention group
Group type: EXPERIMENTAL
Intervention: TST followed by QFT if TST was positive
Number of subjects: 0
Study 29479457 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured internet-based exercise program (e-training)
Number of subjects: 0
Study 29479457 — intervention group
Group type: COMPARATOR
Intervention: No e-training intervention (control group)
Number of subjects: 0
Study 29479457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 0
Study 29479466 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioural weight loss programme
Number of subjects: 40
Study 29479466 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard programme plus partner involvement (Enhanced)
Number of subjects: 40
Study 29479473 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0
Study 29479473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29480210 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS-HTTRX trial (NCT02519036)
Number of subjects: 0
Study 29480210 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISION-HD1 (NCT03225833)
Number of subjects: 0
Study 29480210 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISION-HD2 (NCT03225846)
Number of subjects: 0
Study 29480210 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRST-HD deutetrabenazine trial (NCT01795859)
Number of subjects: 0
Study 29480357 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg/week for 24 weeks followed by ETN for 28 weeks
Number of subjects: 53
Study 29480357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) for 28 weeks after initial treatment with ETN
Number of subjects: 53
Study 29480357 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 53
Study 29480357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 53
Study 29480444 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise behavior and physical fitness assessment shortly after diagnosis
Number of subjects: 227
Study 29480444 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exercise and walking behavior
Number of subjects: 227
Study 29480444 — intervention group
Group type: EXPERIMENTAL
Intervention: Current exercise behavior
Number of subjects: 227
Study 29481376 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 powered exoskeleton with electroencephalography-based brain-machine interface
Number of subjects: 5
Study 29481659 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy
Number of subjects: 53
Study 29481737 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept (weight-tiered: 50 mg for 10 to <25 kg, 87.5 mg for 25 to <50 kg, 125 mg for ≥50 kg) administered weekly for 24 months.
Number of subjects: 0
Study 29481881 — intervention group
Group type: EXPERIMENTAL
Intervention: Filovirus Animal Non-Clinical Group assay
Number of subjects: 0
Study 29481881 — intervention group
Group type: COMPARATOR
Intervention: Alpha Diagnostics International assay
Number of subjects: 0
Study 29481926 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 units of unfractionated heparin (UFH)
Number of subjects: 36
Study 29481970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vedolizumab and adalimumab
Number of subjects: 0
Study 29481970 — intervention group
Group type: COMPARATOR
Intervention: Current therapies (biologic agents)
Number of subjects: 0
Study 29482538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT)
Number of subjects: 0
Study 29482538 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 0
Study 29482554 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity thresholds identified through regression and ROC analyses
Number of subjects: 120
Study 29482554 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity thresholds identified through regression and ROC analyses
Number of subjects: 120
Study 29482554 — intervention group
Group type: EXPERIMENTAL
Intervention: Heuristic cadence thresholds for moderate intensity
Number of subjects: 120
Study 29482554 — intervention group
Group type: EXPERIMENTAL
Intervention: Heuristic cadence thresholds for vigorous intensity
Number of subjects: 120
Study 29482554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of heuristic thresholds
Number of subjects: 120
Study 29482567 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pregnancy
Number of subjects: 0
Study 29482567 — intervention group
Group type: COMPARATOR
Intervention: Pre-eclampsia (PE)
Number of subjects: 0
Study 29482601 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity, low-volume interval training (HIIT-low volume)
Number of subjects: 60
Study 29482601 — intervention group
Group type: COMPARATOR
Intervention: Continuous aerobic exercise (CAE)
Number of subjects: 60
Study 29482616 — intervention group
Group type: EXPERIMENTAL
Intervention: CCQ cutoff of 1.4
Number of subjects: 126
Study 29482616 — intervention group
Group type: EXPERIMENTAL
Intervention: CCQ
Number of subjects: 126
Study 29483030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza vaccine (LAIV)
Number of subjects: 454
Study 29483030 — intervention group
Group type: COMPARATOR
Intervention: Control group (children not enrolled in the NASIMMUNE study)
Number of subjects: 454
Study 29483101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg)
Number of subjects: 51
Study 29483841 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral microvascular endothelial dysfunction (ED)
Number of subjects: 874
Study 29483841 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPA negativity
Number of subjects: 874
Study 29483841 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher triglycerides concentrations
Number of subjects: 874
Study 29483892 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet (MAD) for 12 weeks
Number of subjects: 18
Study 29483892 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mean monthly number of attacks
Number of subjects: 18
Study 29483892 — intervention group
Group type: EXPERIMENTAL
Intervention: End of 3-month diet mean monthly number of attacks
Number of subjects: 18
Study 29483909 — intervention group
Group type: COMPARATOR
Intervention: Autoantibodies (AAb) against G protein-coupled receptors (GPCRs) in patients with POAG and OHT.
Number of subjects: 0
Study 29484099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunbeds with UVB radiation
Number of subjects: 0
Study 29484172 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnoeic oxygenation (3 l/min oxygen by nasal cannula)
Number of subjects: 30
Study 29484172 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study 29484172 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnoeic oxygenation
Number of subjects: 30
Study 29484177 — intervention group
Group type: EXPERIMENTAL
Intervention: MUAC insertion tape
Number of subjects: 21
Study 29484177 — intervention group
Group type: COMPARATOR
Intervention: Click-MUAC devices
Number of subjects: 21
Study 29484197 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week bilingual yoga intervention adapted for arthritis
Number of subjects: 0
Study 29484197 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted self-interview (CASI) for data collection
Number of subjects: 0
Study 29484198 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) program consisting of exercises designed to improve balance and gait, conducted over 8 weeks, twice weekly.
Number of subjects: 0
Study 29484198 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the current standard of care following STN-DBS, which does not include prescription of PT.
Number of subjects: 0
Study 29484198 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) program
Number of subjects: 0
Study 29484495 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 2195
Study 29484495 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone or in combination with a dopamine agonist
Number of subjects: 2195
Study 29484495 — intervention group
Group type: COMPARATOR
Intervention: Dopaminergic monotherapy
Number of subjects: 2195
Study 29484495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine-substituting therapies
Number of subjects: 2195
Study 29484580 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V/PROMUS everolimus-eluting stents
Number of subjects: 2010
Study 29485066 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated adjuvant whole breast/chest wall and/or regional nodal radiation therapy, 34 Gy in 10 fractions within 2 weeks, followed by a boost of 10 Gy in 5 fractions within 1 week for BCS patients.
Number of subjects: 50
Study 29485066 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of 35 Gy in 15 fractions within 3 weeks (not explicitly detailed in the abstract).
Number of subjects: 50
Study 29485355 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical homeopathy for prophylaxis of recurrent urinary tract infections
Number of subjects: 0
Study 29485933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise breaks (25% of heart rate reserve)
Number of subjects: 39
Study 29485933 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise breaks (50% of heart rate reserve)
Number of subjects: 39
Study 29485933 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise breaks (75% of heart rate reserve)
Number of subjects: 39
Study 29485933 — intervention group
Group type: COMPARATOR
Intervention: Sedentary computer game breaks
Number of subjects: 39
Study 29485933 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall condition effect
Number of subjects: 39
Study 29485988 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCESS-care
Number of subjects: 115
Study 29486396 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 150
Study 29486396 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day (sensitivity analysis)
Number of subjects: 150
Study 29486663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 112